# A Phase 3 Study of UGN-103 for Treatment of Patients With Low-grade Intermediate-risk Non-muscle Invasive Bladder Cancer

> **NCT06331299** · PHASE3 · ACTIVE_NOT_RECRUITING · sponsor: **UroGen Pharma Ltd.** · enrollment: 99 (actual)

## Conditions studied

- Bladder Cancer
- Urothelial Carcinoma
- Urothelial Carcinoma Bladder

## Interventions

- **DRUG:** UGN-103

## Key facts

- **NCT ID:** NCT06331299
- **Lead sponsor:** UroGen Pharma Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2024-08-29
- **Primary completion:** 2025-09-11
- **Final completion:** 2026-09
- **Target enrollment:** 99 (ACTUAL)
- **Last updated:** 2026-01-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06331299

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06331299, "A Phase 3 Study of UGN-103 for Treatment of Patients With Low-grade Intermediate-risk Non-muscle Invasive Bladder Cancer". Retrieved via AI Analytics 2026-09-09 from https://api.ai-analytics.org/clinical/NCT06331299. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*